It has become increasingly clear that new approach methodologies (NAMs)—when combined with knowledge of the pathway, results of pharmacology studies, and other relevant data—may offer ways to reduce animal testing.
Similar Posts
Early Alert: Wound and Burn Dressing Issue from Integra LifeSciences
Integra is removing all MediHoney Wound and Burn products and certain lots of CVS Wound Gel that may have breached sterile barriersClinical Decision Support Software
This guidance clarifies the scope of FDA’s oversight of clinical decision support software intended for health care professionals (HCPs) as devices.Lupin Limited Unit 2 – 7/17/2025
Lupin Limited Unit 2 – 7/17/2025. Country: India. Record Type: 483Alert: Automated Impella Controller Correction due to Cybersecurity Issue from Abiomed
Abiomed has issued a letter to affected customers of cybersecurity vulnerabilities related to the operating system in the Automated Impella ControllerFDA Pilots Faster Clarifications to Meeting Minutes
The U.S. Food and Drug Administration today announced a pilot program designed to streamline communications with sponsors following formal meetings.FDA-TRACK: Biosimilar User Fee Act Procedural Notification Goals Summary
FDA-TRACK: Biosimilar User Fee Act Procedural Notification Goals Summary